A Class action Taxotere Lawsuit against Sanofi-Aventis alleges that the company failed to adequately warn patients about the dangers of Taxotere. The lawsuit was filed by a woman in California, who says the company is complicit in the problem through misleading advertising and obfuscation of facts. The FDA has criticized the company’s labeling and advertising, and a judge in Louisiana has upheld a judgment against it.
Sanofi-Aventis failed to provide adequate warnings
A Taxotere Lawsuit filed by Veronica Smith, a Louisiana woman who underwent five Taxotere treatments, alleges that the drug caused permanent hair loss, mental anguish, and loss of earnings. Smith alleges that Sanofi failed to adequately warn physicians about the drug, and failed to disclose research on the drug’s safety. However, a jury in New Orleans rejected Smith’s claim, saying that she did not demonstrate that Sanofi-Aventis had failed to provide adequate warnings.
Phillips’ complaint stems from multidistrict litigation filed in the Eastern District of Louisiana. The Judicial Panel on Multidistrict Litigation centralized a number of actions, including the claim that Sanofi failed to adequately warn patients about the risk of permanent hair loss from Taxotere. In October 2016, the Judicial Panel ruled that Sanofi failed to provide adequate warnings about Taxotere.
Class action lawsuits are pending for Taxotere
More than 1,000 Taxotere lawsuits have been filed in the Eastern District of Louisiana and are undergoing pretrial coordination. According to the lawsuits, the drug manufacturer Sanofi-Aventis knowingly misrepresented information in their advertising to conceal the risk of permanent hair loss. However, the company has a history of false advertising and misleading consumers about the effectiveness of its drugs.
Although Taxotere Lawsuit is a life-saving drug, it is not right that it causes unnecessary pain and suffering to cancer patients. Many cancer survivors have already lost so many of their personal choices because of their illness. Getting compensation will allow them to focus on healing and rebuilding their lives. The lawyers at McIntyre Law believe that victims of cancer shouldn’t be the victims of corporate misconduct. With their proven track record, the lawyers at McIntyre Law have successfully fought for the rights of cancer patients.
FDA has criticized Sanofi for its labeling
The FDA has criticized Sanofi for its mislabeling of Taxotere. This drug has been approved by the FDA since 2009. However, the FDA has the authority to change a drug’s approval if it has been marketed with misleading or unsubstantiated claims. In this case, Sanofi misbranded Taxotere because it lacked a warning about permanent hair loss.
The FDA has taken issue with the marketing campaign for Taxotere, which is also used to treat cancers that were not previously approved by the agency. Sanofi’s marketing campaign for the drug incorporated a gloss that summed up its clinical trial. The FDA has since criticized the drug maker for not removing previous references to drug development. Sanofi’s actions have led to an investigation by the FDA into the drug’s labeling.
Class action lawsuits are pending for Taxotere in Louisiana
Currently, multiple class action lawsuits are pending in Louisiana involving the cancer drug Taxotere. These lawsuits allege that Taxotere causes permanent hair loss. The drug maker is accused of knowing about this side effect but failed to warn patients. Taxotere was marketed as more effective than other chemotherapy drugs, which do not cause permanent hair loss. A trial for the first bellwether case of this MDL is scheduled for May 21, 2019.
A recent trial in Louisiana concluded that the drug caused permanent hair loss. A jury found in favor of Sanofi. The case is one of the largest multidistrict litigations in the country, and the jury found against the pharmaceutical company. Thousands of plaintiffs have sued Sanofi for failing to properly warn patients about the risk of permanent hair loss. In the Louisiana trial, the company denied its claims and is appealing the verdict.
Class action lawsuits for Taxotere in Louisiana
Two Louisiana courts have consolidated class action lawsuits related to the advertising of Taxotere. The lawsuits were originally filed in federal court nationwide in the Eastern District of Louisiana. The court widened the scope of the litigation, allowing generic versions of the drug to be included. The number of pending lawsuits nearly tripled between December and January, going from 300 to more than 2,000.
The plaintiffs in Taxotere Bayard advertising in Louisiana argued that the ‘contra non valentem’ doctrine applied to their case, since they were unaware they had a cause of action against the drug company. The plaintiffs argued that they had only learned of the link within a year of being diagnosed with cancer. In light of this ruling, more plaintiffs are bringing suits in Louisiana.